- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-CYP3A5 monoclonal antibody
Pre-made anti-CYP3A5 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to CYP3A5/CYP3A5 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-IP0650-Ab-1/ GM-Tg-hg-IP0650-Ab-2 | Anti-Human CYP3A5 monoclonal antibody | Human |
| GM-Tg-rg-IP0650-Ab-1/ GM-Tg-rg-IP0650-Ab-2 | Anti-Rat CYP3A5 monoclonal antibody | Rat |
| GM-Tg-mg-IP0650-Ab-1/ GM-Tg-mg-IP0650-Ab-2 | Anti-Mouse CYP3A5 monoclonal antibody | Mouse |
| GM-Tg-cynog-IP0650-Ab-1/ GM-Tg-cynog-IP0650-Ab-2 | Anti-Cynomolgus/ Rhesus macaque CYP3A5 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-IP0650-Ab-1/ GM-Tg-felg-IP0650-Ab-2 | Anti-Feline CYP3A5 monoclonal antibody | Feline |
| GM-Tg-cang-IP0650-Ab-1/ GM-Tg-cang-IP0650-Ab-2 | Anti-Canine CYP3A5 monoclonal antibody | Canine |
| GM-Tg-bovg-IP0650-Ab-1/ GM-Tg-bovg-IP0650-Ab-2 | Anti-Bovine CYP3A5 monoclonal antibody | Bovine |
| GM-Tg-equg-IP0650-Ab-1/ GM-Tg-equg-IP0650-Ab-2 | Anti-Equine CYP3A5 monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-IP0650-Ab-1/ GM-Tg-hg-IP0650-Ab-2; GM-Tg-rg-IP0650-Ab-1/ GM-Tg-rg-IP0650-Ab-2; GM-Tg-mg-IP0650-Ab-1/ GM-Tg-mg-IP0650-Ab-2; GM-Tg-cynog-IP0650-Ab-1/ GM-Tg-cynog-IP0650-Ab-2; GM-Tg-felg-IP0650-Ab-1/ GM-Tg-felg-IP0650-Ab-2; GM-Tg-cang-IP0650-Ab-1/ GM-Tg-cang-IP0650-Ab-2; GM-Tg-bovg-IP0650-Ab-1/ GM-Tg-bovg-IP0650-Ab-2; GM-Tg-equg-IP0650-Ab-1/ GM-Tg-equg-IP0650-Ab-2 |
| Products Name | Anti-CYP3A5 monoclonal antibody |
| Format | mab |
| Target Name | CYP3A5 |
| Protein Sub-location | Introcelluar Protein |
| Category of antibody | |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
| Tag | Fc |
| Products description | Pre-made anti-CYP3A5 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | GM-Tg-g-IP0650-Ag-1 | Recombinant multi-species CP3A5/ CYP3A5/ CP35 protein |
| ORF Viral Vector | vGMAP000326 | Human CYP3A5 Adenovirus particle |
| ORF Viral Vector | pGMLP000482 | human CYP3A5 Lentivirus plasmid |
| ORF Viral Vector | vGMLP000482 | human CYP3A5 Lentivirus particle |
| ORF Viral Vector | vGMAP000341 | Human CYP3A5 Adenovirus particle |
| ORF Viral Vector | pGMAP000341 | Human CYP3A5 Adenovirus plasmid |
| ORF Viral Vector | pGMAP000326 | Human CYP3A5 Adenovirus plasmid |
| ORF Viral Vector | pGMLPm004135 | mouse Cyp3a11 Lentivirus plasmid |
| ORF Viral Vector | vGMLPm004135 | mouse Cyp3a11 Lentivirus particle |
Target information
| Target ID | GM-IP0650 |
| Target Name | CYP3A5 |
| Gene ID | 1577 |
| Gene Symbol and Synonyms | CP35,CYP3A5,CYPIIIA5,P450PCN3,PCN3 |
| Uniprot Accession | P20815 |
| Uniprot Entry Name | CP3A5_HUMAN |
| Protein Sub-location | Introcelluar Protein |
| Category | |
| Disease | Cancer |
| Gene Ensembl | ENSG00000106258 |
| Target Classification | Tumor-associated antigen (TAA) |
The target: CYP3A5, gene name: CYP3A5, also named as CP35, CYPIIIA5, P450PCN3, PCN3. This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. The encoded protein metabolizes drugs as well as the steroid hormones testosterone and progesterone. This gene is part of a cluster of cytochrome P450 genes on chromosome 7q21.1. Two pseudogenes of this gene have been identified within this cluster on chromosome 7. Expression of this gene is widely variable among populations, and a single nucleotide polymorphism that affects transcript splicing has been associated with susceptibility to hypertensions. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Apr 2014].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
